

Dear Healthcare Practitioner

Re: Importance to prescribe Zeyzelf[®] twice weekly rivastigmine transdermal patch by brand name.

It has come to our attention that there appears to be several technical problems with how Zeyzelf[®] twice weekly rivastigmine patches are listed in both Emis and SystmOne primary care prescribing systems.

Both systems do not allow accurate prescribing with the correct dosage instructions when prescribing Zeyzelf[®] generically as 'rivastigmine twice weekly transdermal patches 4.6mg/24h or rivastigmine twice weekly transdermal patches 9.5mg/24h'.

We are working as quickly as we can with the relevant organisations to find a resolution to this issue, but in the interim, to ensure your patients receive the twice weekly Zeyzelf[®] patch with the correct dosage instructions, can you ensure any prescription or referral letter to primary care specifically requests Zeyzelf[®] to be written on the prescription. Please note, there is no additional cost to the NHS by writing Zeyzelf[®] by brand as it is the only twice weekly patch available in the UK and the reimbursement price remains the same whether you prescribe it by brand or generically at £35.09¹ for 8 patches (28-day supply) for both dose strengths.

I also take this opportunity to confirm that the supply chain for Zeyzelf[®] is robust as it is manufactured in Luye's own specialist facility in Germany and in the UK we hold at least 4 months' supply at any time with distribution through the mainline wholesaler AAH.

Thank you for your attention to this important matter.



Andy Farrant
General Manager



Adverse events should be reported.
Reporting forms and information can be found at: <https://yellowcard.mhra.gov.uk/>
Adverse events should also be reported to Luye Pharma Ltd at safety@luyepharma.co.uk

For more information visit:
www.luye.co.uk/product/zeyzelf/

1. <https://bnf.nice.org.uk/drugs/rivastigmine/medicinal-forms/#transdermal-patch>

Scan QR code
for prescribing
information

